Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.31 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.31 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.31 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12891020 | 1.00 | ALDH1A1 (0.35) | ALDH1A1KDM4ELMNAMAPTLTA4H | |
| SCHEMBL12891053 | 1.00 | ALDH1A1 (0.35) | ALDH1A1KDM4ELMNAMAPTLTA4H | |
| SCHEMBL14505174 | 0.89 | ALDH1A1 (0.40) | ALDH1A1KDM4ELMNAMAPTLTA4H | |
| SCHEMBL14505177 | 0.89 | ALDH1A1 (0.40) | ALDH1A1KDM4ELMNAMAPTLTA4H | |
| SCHEMBL14504090 | 0.89 | ALDH1A1 (0.40) | ALDH1A1KDM4ELMNAMAPTLTA4H | |
| SCHEMBL13133936 | 0.88 | ALDH1A1 (0.40) | ALDH1A1KDM4ELMNAMAPTLTA4H | |
| SCHEMBL25588744 | 0.86 | LTA4H (0.34) | LTA4H | |
| SCHEMBL10159882 | 0.83 | KCNQ3 (0.33) | ALDH1A1KDM4ELMNAMAPTKCNQ3 | |
| SCHEMBL24791053 | 0.82 | GPR119 (0.36) | LTA4HGRIN1GRIN2BBACE1 | |
| SCHEMBL26713407 | 0.81 | ALDH1A1 (0.31) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365511-A1 | Antiviral Pyrazolopiridinone Compounds | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-20230365511-A1 | Antiviral Pyrazolopiridinone Compounds | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230242544-A1 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-9566312-B2 | Cyclic peptides and use as medicines | NOVARTIS AG (CH) | 2017-02-14 | — | — | US | disclosed |
| US-20150306172-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | NOVARTIS AG (CH) | 2015-10-29 | — | — | US | disclosed |
| US-9072696-B2 | Cyclic peptides and use as medicines | NOVARTIS AG (CH) | 2015-07-07 | — | — | US | disclosed |
| US-20140134132-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | NOVARTIS AG (CH) | 2014-05-15 | — | — | US | disclosed |
| US-20100249084-A1 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2010-09-30 | — | — | US | disclosed |
| WO-2008116185-A2 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249084-A1 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA3, ADORA1, ADORA2A | ALDH1A1 381/4885KDM4E 3894/4885LMNA 4312/4885 |
| US-20230242544-A1 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | ALDH1A1 1817/4885KDM4E 2736/4885LMNA 3720/4885 |
| US-20140134132-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | PPIF, VIP, FKBP1B | ALDH1A1 4005/4885KDM4E 4822/4885LMNA 2696/4885 |
| US-20150306172-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | PPIF, VIP, MAVS | ALDH1A1 3830/4885KDM4E 4837/4885LMNA 2491/4885 |
| US-20230365511-A1 | Antiviral Pyrazolopiridinone Compounds | ZC3HAV1, ZC3HAV1L, RPL35 | ALDH1A1 2877/4885KDM4E 473/4885LMNA 4148/4885 |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | ALDH1A1 1158/4885KDM4E 3094/4885LMNA 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.